Stockscreener 앱 받기
29.90
3.57%
1.03
시간 외 거래:
29.91
0.01
+0.03%
전일 마감가:
$28.87
열려 있는:
$29.18
하루 거래량:
1.05M
Relative Volume:
0.79
시가총액:
$1.72B
수익:
$11.13M
순이익/손실:
$-81.99M
주가수익비율:
-16.62
EPS:
-1.7988
순현금흐름:
$-68.38M
1주 성능:
-3.24%
1개월 성능:
+5.47%
6개월 성능:
+358.59%
1년 성능:
+121.81%
1일 변동 폭
$29.04
$30.44
1주일 범위
$28.15
$32.45
52주 변동 폭
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
29.90 | 1.66B | 11.13M | -81.99M | -68.38M | -1.7988 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
Patterns Watch: Is Capricor Therapeutics Inc stock a value trapWeekly Profit Summary & High Accuracy Investment Signals - baoquankhu1.vn
Merger Talk: How does Capricor Therapeutics Inc perform in inflationary periods2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Capricor Therapeutics (CAPR) reports positive phase 3 HOPE-3 data and $318M 2025 cash balance - MSN
Technical Reactions to CAPR Trends in Macro Strategies - Stock Traders Daily
Capricor Therapeutics Tokenized Stock (Ondo) price today, CAPRon to USD live price, marketcap and chart - CoinMarketCap
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) added to S&P Biotechnology Select Industry Index - marketscreener.com
Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Capricor Therapeutics (CAPR) price target increased by 32.98% to 51.82 - MSN
Why Capricor Therapeutics (CAPR) Is Down 8.0% After FDA Resumes Deramiocel Review And Phase 3 Update - Sahm
Growth Review: Is Capricor Therapeutics Inc a defensive stock2026 EndofYear Setup & Long-Term Safe Return Strategies - baoquankhu1.vn
Capricor Therapeutics Pipeline Overview: Deramiocel for Muscular Dystrophy and Exosome-Based Vaccine Development (2025-2026) - Minichart
Decoding Capricor Therapeutics Inc (CAPR): A Strategic SWOT Insight - GuruFocus
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 - 富途牛牛
CAPR SEC FilingsCapricor Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance - Insider Monkey
Capricor Therapeutics 2025 10-K: Revenue $0, EPS $(2.26) - TradingView
Deramiocel DMD program and big Nippon Shinyaku deals at Capricor (NASDAQ: CAPR) - Stock Titan
About Capricor Therapeutics (Ondo Tokenized) - Coinbase
13 Best Hot Stocks to Buy According to Analysts - Insider Monkey
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript - Insider Monkey
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits
A Look At Capricor Therapeutics’ (CAPR) Valuation After FDA Resumes Deramiocel Review On New HOPE-3 Data - Sahm
Q1 Earnings Forecast for CAPR Issued By HC Wainwright - MarketBeat
Capricor Therapeutics Hits Day High with 8.06% Surge in Stock Price - Markets Mojo
Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? - Yahoo Finance
Capricor Therapeutics (CAPR) Posts US$50 Million H1 Loss Reinforcing Bearish Cash Burn Narrative - simplywall.st
CAPR Stock: Analyst B. Riley Securities Raises Price Target to $ - GuruFocus
Capricor Therapeutics Nears Key Milestones After Earnings Call - TipRanks
Deramiocel Poised to Be First Therapy for DMD's Cardiac and Skeletal Issues - Intellectia AI
Capricor Therapeutics, Inc. (CAPR) Presents at 2026 MDA Clinical & Scientific ConferenceSlideshow - Seeking Alpha
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel (NASDAQ:CAPR) - Seeking Alpha
Capricor Therapeutics (CAPR) Shares Recommended for Purchase Ami - GuruFocus
Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss - marketscreener.com
B. Riley Financial Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price - MarketBeat
CAPR Stock: Analyst B. Riley Securities Raises Price Target to $63 | CAPR Stock News - GuruFocus
Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates - Benzinga
CAPR: Piper Sandler Raises Price Target to $58, Reiterates Overw - GuruFocus
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.3%Time to Sell? - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Given Overweight Rating at Piper Sandler - MarketBeat
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings - AOL.com
Trading the Move, Not the Narrative: (CAPR) Edition - Stock Traders Daily
Oppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR) - The Globe and Mail
Cantor Fitzgerald Remains a Buy on Capricor Therapeutics (CAPR) - The Globe and Mail
B. Riley Adjusts Price Target on Capricor Therapeutics to $63 From $50, Maintains Buy Rating - marketscreener.com
Pier Capital LLC Boosts Stock Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Why Did Compass Pathways Stock Rocket Higher Today? - AOL.com
CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval - Stocktwits
Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone - MSN
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy - Sahm
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):